|
|Section2= |Section3= }} Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc. It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers. It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).〔(Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease ), 2002〕 It is photoactivated by 732 nm light which allows greater depth of penetration.〔http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T〕 ==Clinical trials== Phase II clinical trials were in progress in 1999.〔(Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT ), 1999〕 A phase I trial for prostate cancer reported in 2009. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「motexafin lutetium」の詳細全文を読む スポンサード リンク
|